The glucagon in retatrutide refers to glucagon-receptor agonism, the third of the molecule’s three receptor activities. Retatrutide is a triple agonist that acts on the GLP-1 receptor, the GIP receptor, and the glucagon receptor, and the glucagon arm is the one that sets it apart from GLP-1-only peptides and from GLP-1-plus-GIP dual agonists. Glucagon does not sit in the vial as a separate hormone, it is a receptor that the peptide is built to switch on.
For the molecule’s identity and full mechanism, see the companion guides on what retatrutide is and its mechanism of action. retatrutide research peptides are supplied for laboratory research use only, and what follows describes receptor pharmacology, not any direction for use.
The glucagon receptor is one of three targets
In retatrutide, glucagon activity means the peptide binds to and activates the glucagon receptor, written GCGR. This is a G-protein-coupled receptor, the same broad class as the GLP-1 and GIP receptors, so all three arms feed into a shared cyclic AMP and protein kinase A signaling pathway inside the cell.
Adding this receptor is the defining idea of the molecule. Single agonists act on GLP-1 alone, dual agonists add GIP, and retatrutide layers glucagon-receptor activity on top of both. That extra arm is exactly why it is classed as a triple, rather than a dual, agonist, and it is the most useful thing to understand about the glucagon component.
What the glucagon receptor does in the body
Glucagon is best known as the counter-regulatory hormone to insulin. In normal physiology it is released when blood glucose falls, and it acts primarily on the liver, which along with the kidney carries the highest density of glucagon receptors. Tissues such as muscle, fat, and the heart carry far fewer, so the liver is where most glucagon action happens.
At the liver, glucagon raises glucose output by stimulating glycogenolysis, the breakdown of stored glycogen, and gluconeogenesis, the making of new glucose. According to the NIH Endotext review of glucagon physiology, it also promotes the formation of non-carbohydrate energy sources, driving lipolysis, fatty acid oxidation, and ketone production while reducing lipogenesis. These are the receptor-level actions the glucagon arm brings to a triple agonist.
Why glucagon is tied to energy expenditure and lipids
Beyond glucose, glucagon signaling has drawn research interest for its effects on energy use and hepatic fat. In animal models, increased glucagon-receptor signaling has been linked to improved lipid metabolism and reduced fat accumulation in the liver, and glucagon supports intracellular lipolysis and fatty acid oxidation through the cyclic AMP and protein kinase A pathway.
That energy-expenditure angle is why glucagon was added to retatrutide. In diet-induced obese mice, the glucagon arm of retatrutide was associated with an increase in energy expenditure, a preclinical finding the discovery work attributed specifically to glucagon-receptor engagement rather than to the two incretin arms.
Why glucagon is combined with GLP-1 and GIP
Glucagon on its own has a catch: activating the glucagon receptor tends to raise blood glucose, which runs opposite to the goal of a metabolic agent. The research solution, described in the glucagon literature, is to pair glucagon activity with GLP-1 activity, so the incretin arm restrains the glucose-raising effect while the lipolysis and energy-expenditure actions are retained.
Retatrutide does exactly that, and it also tunes the balance. It is most potent at the GIP receptor and least potent at the glucagon receptor, with a measured glucagon-receptor potency near 5.79 nanomolar in cyclic AMP assays. Setting glucagon activity lower keeps it from overwhelming the incretin arms, so the three receptors work together rather than pulling in opposite directions.
How the glucagon activity was characterized
The glucagon-receptor pharmacology of retatrutide, its full-agonist behavior, and the mouse energy-expenditure findings come from the primary discovery research, and the broader biology of the receptor is summarized in the NIH Endotext review of glucagon physiology. Reading both keeps the description accurate.
The key point to carry away is a matter of framing. Glucagon in retatrutide is a receptor target that the peptide activates, not a hormone added to the product, and describing the molecule by its three receptors, GLP-1, GIP, and glucagon, is more precise than any shorthand.
Research use only
This article explains the role of the glucagon receptor within retatrutide research peptides. It is a scientific reference and is not a statement of regulatory approval, medical availability, or any instruction for use.
All products are supplied for research and development use only. They are not for human or veterinary use, and they are not intended to diagnose, treat, cure, or prevent any disease. Anyone using this material is responsible for handling it in line with institutional requirements and applicable law.